Ting Jiang

Dr. Ting Jiang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
HLHao Lv
Hao Lv
YWYan Wang
Yan Wang
GZGe Zhang
Ge Zhang
XWXingyu Wang
Xingyu Wang
ZHZhimu Hu
Zhimu Hu
JWJiuxiang Wang
Jiuxiang Wang
The current literature lacks robust clinical data and evidence delineating the relationship between obesity measurement indexes and knee osteoarthritis (KOA). Consequently, this investigation seeks to elucidate the potential link between obesity measurement indexes and KOA among Chinese adults in a nationally representative study. Firstly, this research performed an observational study in the China Health and Retirement Longitudinal Study (CHARLS). The variables were extracted from interviews and compared between KOA and non-KOA participants. The relationship between obesity measurement indexes and KOA was analyzed by multivariate logistic regression. Restricted cubic spline (RCS) regression tests the nonlinearity of the relationship between obesity measurement indexes and KOA. Subgroup analyses were performed by sex to verify the robustness of the findings. In this cross-sectional analysis, we found a positive association between obesity measurement indexes and KOA. These results did not change on multiple imputations(BMI: OR = 1.02, 95% CI, 1.01–1.04, P < 0.05; WHtR: OR = 2.85, 95% CI, 1.08–7.51, P < 0.05; BRI: OR = 1.07, 95% CI, 1.01–1.12, P < 0.05; BFP: OR = 1.02 95% CI, 1.00-1.03, P < 0.05). All the effects of obesity measurement indexes with KOA are present in females. None of the stratifying variables significantly affected the association between obesity measurement indexes and KOA. RCS regression test revealed the linear positive correlation between obesity measurement indexes and KOA. In this cross-sectional study, we found a significant association between obesity measurement indexes and KOA. This relationship is not affected by stratification and confounding factors.

15 May 2020 in Medicine
Verified
Journal Article
Open access
QMQi-Ming Ma
Qi-Ming Ma
GHGuo-Song Han
Guo-Song Han
BLBo-Wen Li
Bo-Wen Li
XLXiao-Jing Li
Xiao-Jing Li
TJTing Jiang
Ting Jiang
Background: Antifibrinolytic agents have been successfully used to reduce blood transfusion demand in patients undergoing elective knee arthroplasty. The purpose of this study was to investigate different antifibrinolytic agents for patients undergoing total-knee arthroplasty (TKA). Methods: We searched the randomized controlled trials assessing the effect of antifibrinolytic agents on TKA in MEDLINE, PubMed, Embase, and the Cochrane Library. Participants are divided into antifibrinolytic agent group and control group under TKA. Double extraction technology is used and the quality of its methodology is evaluated before analysis. Outcomes analyzed included blood loss, number of blood transfusions, rates of blood transfusion, and deep vein thrombosis (DVT). Results: A total of 28 randomized controlled trials involving 1899 patients were included in this study. Compared with the control group, the antifibrinolytic agents group exhibited significantly reduced the amounts of total blood loss (weighted mean difference [WMD] with 95% confidence interval [CI]: −272.19, −338.25 to −206.4), postoperative blood loss (WMD with 95% CI: −102.83, −157.64 to −46.02), average units of blood transfusion (risk ratio with 95% CI: 0.7, 0.12 to 0.24), and average blood transfusion volumes (WMD with 95% CI: −1.34, −1.47 to −1,21). Antifibrinolytic agents significantly reduced the rate of blood transfusions and did not increase the occurrence risk of intraoperative blood loss and DVT. Several limitations should also be acknowledged such as the heterogeneity among the studies. Conclusion: The application of antifibrinolytic agents can significantly reduce blood loss and blood transfusion requirements. Additionally, these agents did not increase the risk of DVT in patients undergoing TKAs.

29 April 2025 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
QCQingsong Chu
Qingsong Chu
XWXingyu Wang
Xingyu Wang
HLHao Lv
Hao Lv
YZYao Zhou
Yao Zhou
TJTing Jiang
Ting Jiang
In this study, a computed tomography (CT)-vision transformer (ViT) framework for diagnosing lumbar disc herniation (LDH) was proposed for the first time by taking advantage of the multidirectional advantages of CT and a ViT. The proposed ViT model was trained and validated on a dataset consisting of 983 patients, including 2100 CT images. We compared the performance of the ViT model with that of several convolutional neural networks (CNNs), including ResNet18, ResNet50, LeNet, AlexNet, and VGG16, across two primary tasks: vertebra localization and disc abnormality classification. The integration of a ViT with CT imaging allowed the constructed model to capture the complex spatial relationships and global dependencies within scans, outperforming CNN models and achieving accuracies of 97.13% and 93.63% in terms of vertebra localization and disc abnormality classification, respectively. The performance of the model was further validated via gradient-weighted class activation mapping (Grad-CAM), providing interpretable insights into the regions of the CT scans that contributed to the model predictions. This study demonstrated the potential of a ViT for diagnosing LDH using CT imaging. The results highlight the promising clinical applications of this approach, particularly for enhancing the diagnostic efficiency and transparency of medical AI systems.

9 August 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
HLHao Lv
Hao Lv
JWJiuxiang Wang
Jiuxiang Wang
YZYujun Zhu
Yujun Zhu
ZHZhimu Hu
Zhimu Hu
ZWZiwen Wang
Ziwen Wang
TJTing Jiang
Ting Jiang
Background: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.Methods: Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regressionResults: After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p &lt;0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p &lt;0.05).Conclusion: This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research.

28 October 2025 in European Spine Journal
Verified
Journal Article
Open access
PDF file
YZYinghao Zhu
Yinghao Zhu
YYYuxiang Yang
Yuxiang Yang
HYHairu Yi
Hairu Yi
TJTing Jiang
Ting Jiang
Background Neck pain is a prevalent musculoskeletal disorder whose global epidemiological trends and disease burden remain insufficiently characterized. Using the Global Burden of Disease (GBD) 2021 database, this study systematically analyzes the incidence, prevalence, DALY rates, and temporal trends in disease burden attributable to neck pain from 1990 to 2021. Methods We extracted the incidence, prevalence, and disability-adjusted life year (DALY) rates of neck pain from the 2021 Global Burden of Disease (GBD) database, stratified by country, region, sex, and age group. Trends in the burden of neck pain from 1990 to 2021 were assessed using estimated annual percentage change (EAPC) and 95% confidence intervals (CI). An autoregressive integrated moving average (ARIMA) model was used to project trends from 2022 to 2036. Additional statistical approaches—including decomposition, frontier, and health inequality analyses—were also applied. Results According to the Global Burden of Disease (GBD) 2021 study, the number of prevalent neck pain cases reached 206,029,629 in 2021, nearly doubling since 1990. The age-standardized disability-adjusted life year (DALY) rate (ASDR) for neck pain also exhibited an upward trend. Notably, gender disparities were observed: both the ASDR and the number of cases increased more sharply among women than men, indicating a significantly higher burden for women. Geographically, low- and middle-SDI regions carried a greater disease burden and experienced a more pronounced rise in ASDR. Conversely, high-income regions such as North America and Northern Europe demonstrated the highest risk of neck pain. Frontier analysis identified countries including Austria, Denmark, and the UK as requiring urgent interventions. Health inequality analysis revealed substantial disparities in neck pain burden across countries and regions of differing SDI levels over the past thirty years, with these inequities widening over time. The age-period-cohort (APC) model indicated that the incidence of neck pain rises with age, peaking between 70 and 80 years. Projections from predictive modeling suggest a slow decline in the global burden of neck pain from 2022 to 2036. Conclusions Between 1990 and 2021, the global burden of neck pain increased significantly. Women consistently experienced a higher overall disease burden than men. Persistent disparities were observed across genders, age groups, Socio-demographic Index (SDI) regions, and countries, highlighting the need for targeted health strategies to reduce the worldwide impact of neck pain. Priority interventions should focus on women and lower-SDI regions, where the burden is most pronounced.

4 January 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HLHao Lv
Hao Lv
JWJiuxiang Wang
Jiuxiang Wang
YZYujun Zhu
Yujun Zhu
TJTing Jiang
Ting Jiang
Background. This study used a combination of network pharmacology and experimental confirmation to clarify the mechanism of the compound kidney-invigorating granule (CKG) in treating osteoporosis (OP). Methods. The main bioactive compounds and corresponding targets of CKG were collected and screened via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Yet another Traditional Chinese Medicine (YaTCM), and UniProt databases. Disease targets of OP were summarized in GeneCards and the Comparative Toxicogenomics Database (CTD). Targets of CKG for OP were obtained by Venn diagram. The protein-protein interaction (PPI) network was constructed by the STRING database and then screened for hub genes through Cytoscape 3.7.2 software. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were analyzed and visualized by R software. Then, CB-Dock was used for molecular docking verification. Finally, we confirmed the antiosteoporosis effect of CKG through animal and cell experiments. Results. A total of 250 putative targets were obtained from 65 bioactive compounds in CKG. Among them, 140 targets were related to OP. Topological analysis of the PPI network yielded 23 hub genes. Enrichment analysis showed the targets of CKG in treating OP might concentrate on the MAPK signaling pathway, the TNF signaling pathway, the PI3K-Akt signaling pathway, etc. The results of molecular docking showed the bioactive components in CKG had good binding ability with the key targets. The experimental results showed that CKG-medicated serum had a promoting effect on proliferating hBMSCs, increasing the expression of AKT, PI3K, ERK1, and IkB in cells and decreasing the expression of IKK in cells. Conclusion. CKG has a complex of multicomponent, multitarget, and multipathway. This study lays the theoretical foundation for further in vitro and in vivo experimental studies and further expands the clinical applications of CKG.